Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Treatment time ranged from 12 to146 months (median 47). Nine dogs had been treated with FC, 8 dogs with DOCP and in 10 dogs FC had been changed to DOCP because of poor response or adverse effects. At the time of diagnosis 3 dogs had elevated SDMA whereas Cr was elevated in 8 dogs, both parameters normalized after starting therapy. Two dogs developed persistent elevated SDMA 18 and 32 months after starting therapy with FC and DOCP respectively, followed by an elevated Cr 14 and 4 months later. Clinical signs and further work up were consistent with chronic kidney disease (CKD) in both dogs. Although SDMA was within the reference interval in all other dogs, 3 dogs showed an elevated Cr, being permanent in one of them. A significant correlation between SDMA and Cr was demonstrated (r = 0.35; P = .0013). There was no statistical evidence of any differences in Cr or SDMA between the FC and the DOCP groups.